JSKN016 not checked

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
6 active
6 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Injection; 100 mg (4.0 mL)/vial. Dosage: 6 mg/kg administered via intravenous infusion on Day 1 of each 21-day cycle”In the company’s words, NCT07533123 on ClinicalTrials.gov
Tested for
Advanced Non-small Cell Lung Cancer (2 trials), Triple Negative Breast Cancer, Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer (LABC), Advanced Malignant Solid Tumor
Main trialPhase 3
“Primary Endpoint of this Study: To compare Progression-Free Survival (PFS) (as assessed by a Blinded Independent Review Committee \[BIRC\] based on Response Evaluation Criteria in Solid Tumors \[RECIST v1.1\]) between JSKN016 and Treatment of Physician's Choice (TPC) in participants with unresectable locally advanced, recurrent, or metastatic triple-negative breast cancer (TNBC). To compare Overall Survival (OS) between JSKN016 and TPC in the treatment of unresectable locally advanced, recurrent, or metastatic TNBC.”In the company’s words, NCT07533123 on ClinicalTrials.gov

Other drugs for Advanced Non-small Cell Lung Cancer

All 561 drugs for Advanced Non-small Cell Lung Cancer

Coming up5

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials6

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 17 Mar 2029 A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care
Phase 2Not yet recruiting 30 Jun 2027 Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance: a Phase II Clinical Study
Phase 1/2Recruiting 30 Jun 2027 Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer
Phase 1/2Not yet recruiting Dec 2027 JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer
Phase 1Recruiting 17 May 2026 To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors
Phase 1Recruiting 30 Jun 2028 Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow JSKN016

Following is part of Solo: you see every change to JSKN016 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in